Public Webinar: Can Endpoints from Digital Technology Provide Meaningful Outcomes for HTA?

Welcome from the co-moderators

• 

  Eric Sutherland

  Senior Health Economist, OECD

  Eric is a Senior Health Economist leading the OECD’s work in Digital Health, bringing together policy guidance for digital tools, integrated data, and responsible analytics including artificial intelligence. In that role, he is accountable for measuring and evolving the OECD’s Recommendation on Health Data Governance (2017) and supporting digital health policy that provides data protection (e.g. security and privacy) and timely access to quality data to optimize the use of data for information, insights, and impact among individuals, health workers, policy makers, researchers, and innovators. Prior to joining the OECD, Eric led the Secretariat for a pan-Canadian Health Data Strategy, bringing together experts and governmental leaders from across Canada to establish an integrated health data ecosystem that makes better use of data for health systems, public health, population health, research, and care. Eric authored the Pan-Canadian Heath Data and Information Governance Framework and Toolkit and has taught courses in data science, health data governance, and privacy.

  Bio

  

  Alina Pavel

  RWE4Decisions Secretariat

Presentations

• Strategies for Development, Governance, and Assessment of Digital Health Technologies at Hospital Level
  

  Rossella di Bidino

  Head of the HTA for AI Unit, ALTEMS Università Cattolica

  Rossella Di Bidino is Senior HTA expert who, since 2005, has been working at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome), where she is responsible for the Innovative Medicines Sector of the Technical, ICT and Health Technology Innovation Directorate. She is also the head of the Health Technology Assessment (HTA) and Artificial Intelligence Laboratory of the Alta Scuola di Economia e Management dei Sistemi Sanitari (ALTEMS). She is an active contributor to numerous international and European HTA Networks: the European Network for Health Technology and Assessment (EUnetHTA), the International Network of Agencies for Health Technology Assessment Activities (INAHTA), as well as participated in several European projects related to HTA and real-world data, including the European Digital HTA (EdiHTA) project, Artificial Intelligence for Dementia Prevention (AI-Mind) and More-EUROPA. Since 2022 she also co-chairs the Hospital-Based HTA Interest Group of the Health Technology Assessment International (HTAi) and is member of the Board of the Health Technology Assessment Division (HTAD) of International Federation of Medical and Biological Engineering (IFMBE). Rossella holds a PhD in Health Economics and Management from the Università Cattolica del Sacro Cuore, which she achieved in 2009.

  Bio
• Patient-controlled information flows and HTA in the global cystic fibrosis community
  

  Andreas Hager

  Board Member, Cystic Fibrosis Europe

  Andreas Hager is a board member of Cystic Fibrosis Europe, a learning networks entrepreneur, and a lawyer. His work focuses on the development of learning health systems, health data infrastructure and novel data management concepts in Sweden and the US for chronic care management, quality improvement and research. He has been a cystic fibrosis caregiver for over 20 years now, and has extensive experience with numerous eHealth and home-monitoring tools. Over the last ten years, Andreas has focused on personal data stores and patient-controlled information flows within the realm of rare diseases, especially for young persons with medical complexity. He has been involved in developing an app for young people living with chronic illnesses, allowing them to keep track of their health and strengthen their communication and collaboration with their families and healthcare providers. Andreas holds an LLM from Stockholm University.

  Bio

Panel discussion

• 

  Anja Schiel

  Senior Advisor, Methodologist in Regulatory and Pharmacoeconomic Statistics, Norwegian Medicinal Products Agency (NOMA)

  Anja is Senior Advisor and Methodologist in Regulatory and Pharmacoeconomic Statistics at the Norwegian Medicinal Products Agency (NoMA), working on both regulatory and Health Technology Assessment (HTA) projects. She has been involved in the work of the European Medicines Agency (EMA) as Chair of the Biostatistics Working Party between 2016-2019, and as Chair to the Scientific Advice Working Party between 2019-2022. She now acts as an Alternate Member of the latter and is member of the recently established Methodology Working Party. She has participated in the European Network for Health Technology Assessment’s (EUnetHTA) JA3 and its successor, EUnetHTA 21 with a particular focus on parallel EMA-HTA scientific advices. Anja studied Biology at the Johannes Gutenberg-University, Mainz, Germany. She received her PhD from the Vrije Universiteit in Amsterdam and worked several years as Post-Doc on a range of subjects focusing on oncology, immunology and molecular biology, first at the University of Leiden and later at the University of Oslo.

  Bio
• 

  Lara Wolfson

  Associate Vice-President & Head HTA Statistics, MSD; Co-Chair, PSI/EFPSI HTA Special Interest Group

  Lara Wolfson is an Associate Vice-President and Head of Health Technology Assessment (HTA) Statistics at MSD, where she has been working since 2015. She also co-leads the European Special Interest Group (HTA ESIG) of the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI). Prior to her current position, Lara’s career spans roles at various pharmaceutical companies and the World Health Organisation, where she focused on biostatistics, health technology assesment, vaccines, epidemiology, and health economics. She also held a teaching position at Brigham Young University (US) and the University of Waterloo (Canada). Over the years, Lara has authored of numerous scientific papers, particularly focusing on vaccination and infectious diseases. Lara obtained a PhD in Statistics from Carnegie Mellon University, with an undergraduate background from Simon Fraser University.

  Bio

Q&A with audience

Next steps

Meeting close